Retatrutide in Trials: Doses Studied, Half-Life, and Escalation Protocols

The brief version on dosing

In clinical trials, retatrutide has been given by injection under the skin (subcutaneous), once a week. The doses studied range from 0.5 mg up to 12 mg per week, with participants typically starting at a low dose and stepping up over several weeks to reduce nausea and other GI effects — a process called dose escalation.

The compound has a half-life (the time for blood levels to fall by half) of roughly 6 days, measured in the first human trial. That half-life is what makes weekly dosing work.

Retatrutide is investigational and not approved. There is no approved dosing standard. The information here is a summary of trial protocols from published papers — it describes study design, not personal guidance.

Retatrutide dosage

Phase 1b (2022): Doses of 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg once weekly subcutaneous injection, over 12 weeks in 72 adults with type 2 diabetes ^[4]. This trial established the compound's half-life (~6 days) and dose-response relationship for early weight and glucose effects.

Phase 2 obesity trial (2023): Fixed doses of 1, 4, 8, and 12 mg once weekly subcutaneous injection over 48 weeks in 338 adults with obesity ^[1]. The 12 mg dose produced the -24.2% weight change headline result. Escalation to the target dose was implemented in practice, though the published dose assignments were fixed.

Phase 2 type 2 diabetes trial (2023): Stepwise escalation from 0.5 mg to a maximum of 12 mg once weekly subcutaneous injection over 36 weeks in 281 adults with type 2 diabetes ^[2]. The stepwise design was specifically adopted to manage GI tolerability during the titration phase.

Phase 3 TRANSCEND-T2D-1 (2026): Doses of 4, 8, and 12 mg with dose escalation, subcutaneous once weekly, over 40 weeks in 537 adults with type 2 diabetes ^[12]. This trial confirmed the escalation protocol at Phase 3 scale.

All doses were administered by subcutaneous injection — injected into the fatty tissue under the skin — using the once-weekly schedule dictated by the half-life.

Retatrutide half life

Retatrutide's half-life is approximately 6 days, established in the Phase 1b first-in-human pharmacokinetics study ^[4]. This is achieved by the C20 fatty diacid acylation — a chemical modification of the peptide backbone that causes it to bind to albumin (a blood protein), which dramatically slows its clearance from plasma compared to native GLP-1 or GIP, which have half-lives of minutes.

The 6-day half-life supports once-weekly dosing, reaching pharmacokinetic steady state within approximately 4–5 weeks. It also means that after discontinuation, the compound is not fully cleared for several weeks — relevant to the safety and monitoring context for any research use.

Route of administration

All published retatrutide trials have used subcutaneous injection — administered into the fatty tissue under the skin, typically at the abdomen, thigh, or upper arm. No oral or intravenous formulations have been studied in clinical trials as of the current literature.

The injection frequency is once weekly, consistent across all Phase 1, 2, and 3 protocols.

How to reconstitute retatrutide

This question comes up frequently because gray-market research-labeled retatrutide is sold as a lyophilized (freeze-dried) powder requiring reconstitution before injection. This site does not provide reconstitution instructions.

Here is why that matters: retatrutide is not an approved product. There is no official prescribing information, no validated reconstitution standard, and no regulatory-reviewed stability data for gray-market preparations. In clinical trials, retatrutide was supplied by Eli Lilly as a formulated injectable — investigators did not reconstitute powder. Published trial protocols do not describe powder reconstitution because that was not the format used.

Providing reconstitution instructions for an unverified research-labeled preparation — whose identity, purity, and endotoxin level are unknown — would not be responsible editorial practice. The compound is investigational. Reconstitution guidance belongs to a clinical setting where the product's identity has been verified and a prescriber is present. Neither applies to gray-market material.

Dose escalation and GI tolerability

Across every Phase 2 trial and the Phase 3 TRANSCEND-T2D-1, dose escalation was a key design feature — participants began at a low dose and stepped up over weeks. This approach was adopted specifically because the GI adverse events (nausea, vomiting, diarrhea) that are the compound's primary tolerability challenge are dose-dependent and tend to diminish after the body adjusts to each level.

In Phase 2, nausea affected up to 45% of participants at the 12 mg dose and was the leading driver of the 18% discontinuation rate at that level ^[1]. Slower escalation schedules are the principal management strategy used in trials — they cannot be replicated in unmonitored settings where no clinical oversight is present.

This is a documented finding, not a recommendation. In trial design, it is the reason escalation schedules exist.